Targovax (TRVX) Småprat

Whatsthat · april 25, 2019, 6:42pm

Ras =
Virus=
TRVX =

Cinvest · april 25, 2019, 6:56pm

At det kommer nok en partner på TG dette året, er langt ifra utenkelig.

" Resected Pancreas
TG01 + SoC Phase II
n = TBD
Pursuing academic partnership
o Externally sponsored and
financed (mainly)
o EU or US based"

I tillegg er mOS fremdeles ikke nådd. Dette begynner å se meget bra ut.

At interessen for RAS har tatt en ny positiv vending , bekreftet Wiklund på Radium. Det er moro!

Whatsthat · april 25, 2019, 7:06pm

Nettopp det jeg tenkte vedrørende resected PC. med parker samarbeid på CV’en, så vil det nok gjøre jobben litt lettere. burde spørre de om status på Q1…

BioMed · april 25, 2019, 7:07pm

BioMed · april 25, 2019, 7:20pm

her er faktisk mye nytt

InfoLeecher · april 25, 2019, 8:29pm

Er det ikke feil på slide 25
2nd cohort
3-year OS read out May 2018

skulle ikke det vært 3-year OS read out May 2019?

Sendte en mail til TRVX IR

BioMed · april 25, 2019, 8:55pm

Ja, det stemmer, Feil!!

InVivo · april 26, 2019, 7:03am

Ja, det ser ikke ut som TG er død.

Det blir veldig spennende å se resultatet fra TG02+CPI. TG oppregulerer PD-LI, så det er gode muligheter for at TG+CPI kan gi en høy ORR.

Whatsthat · april 26, 2019, 7:23am

TG har aldri vært død. Om Inoperabel PC data med parker er bra, så tror jeg at TG raskt kan nå markedet da OS er så kort…

TG02+CPI eller generelt TG + CPI, har de startet med dette? Er vel bare mono tg02 vi får nå H1?

InVivo · april 26, 2019, 8:27am

Om det har startet med TG02+CPI vet jeg ikke, men jeg håper det.

Dette er alt jeg vet:

Whatsthat · april 26, 2019, 7:58am

Ok. Forresten, så ser jeg nå at det kommer noe H2:

Dette er nok den POC’en som de har nevnt det siste året…

Krieghoff · april 26, 2019, 10:21am

Nominee konto hos The Bank of New York Mellon fortsetter å øke i TRVX

Danske kontoen er opp med 110 000 aksjer siden Mars

Inn på 18 plass om konto slås sammen

Whatsthat · april 27, 2019, 11:16pm

Skumleste denne og tenkte wow!!, 20% of all cancer, versjon 2.0, et norsk navn, vaksine, colorectal, Australia, dette er da vel Targovax og TG02?

Så fant jeg publilasjonen med resultatene samt universitetet som gjennomførte studien:

Her står det (av 10 pasienter):
Antibody responses to GUCY2C were detected in 10% of patients, while 40% exhibited GUCY2C-specific T-cell responses.

Nå har vel TG02 og Targovax allerede rappotert immun aktivering på 3/3 pasienter også i samme krefttype…

Det er sent og mulig jeg overser noe,men hva er det de andre over egentlig jubler for?

Ramsess · april 28, 2019, 11:56am

Skjønner heller ikke helt hva de jubler for, men “Karen Knudsen” er nok ikke norsk.

https://www.jefferson.edu/university/jmc/departments/cancer-biology/faculty_staff/faculty/knudsen1.html

blaahval · april 29, 2019, 5:56am

Dagens liste:

TekBot · april 30, 2019, 5:00am

30/04-2019 07:00:21: (TRVX) Targovax ASA: Announcement of first quarter 2019

Oslo, Norway, 30 April 2019 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, will announce its first quarter 2019 results on Thursday, 9 May 2019. A
…

Vis børsmeldingen

presentation by Targovax’s management to investors, analysts and the press will
take place in Oslo at 10:00 CET. The results report and the presentation will be
available at www.targovax.com in the Investors section from 07:00 CET.
Presentation
The presentation will take place at 10:00 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo.

The presentation will also be webcast
live (http://webtv.hegnar.no/presentation.php?webcastId=97815727)) and can be
accessed through www.targovax.com (https://www.targovax.com/en/event/q1-2019
-targovax-quarterly-results/).
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
(Targovax@fticonsulting.com)
About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neoantigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

http://www.netfonds.no/quotes/release.php?id=20190430.OBI.20190430S15

Kraakko · april 30, 2019, 8:46am

Targo begynner å bli skremmende billig før vi nærmer oss mai og read outs. Begynner folk å få kalde føtter?

Martins · april 30, 2019, 11:21am

Nop, Citibank N.A. skal ut koste hva det koste vil ser det ut til. Ellers er det ganske rolig

TekBot · april 30, 2019, 11:58am

30/04-2019 13:57:54: (TRVX) Targovax ASA: Minutes from the Annual General Meeting

The annual general meeting was held on 30 April 2019 at the Company’s offices at
Lilleakerveien 2C, 0283 Oslo.

…

Vis børsmeldingen

Please find minutes of the meeting attached.

190430 TRVX AGM
minutes (https://mb.cision.com/Public/17093/2800684/aab5bc3cf811e57e.pdf)
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
(Targovax@fticonsulting.com)
About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s targeted path-to-market indication
is mesothelioma, where the virus is currently being tested in a randomized phase
II trial. Another trial, in checkpoint inhibitor refractory advanced melanoma,
is expected to produce important proof-of-concept immune activation data in
heavily pre-treated patients.

Targovax is also developing a neoantigen cancer vaccine targeting tumors with
oncogenic RAS-mutations, which are known to drive cancer. The TG vaccine program
has shown strong RAS-specific immune activation and a signal of clinical
efficacy in a 32-patient trial with TG01 in resected pancreatic cancer. A next
generation product candidate, TG02 is currently tested in a phase I trial in
colorectal cancer, both as monotherapy and in combination with Keytruda (an anti
-PD1 check point inhibitor).

http://www.netfonds.no/quotes/release.php?id=20190430.OBI.20190430S128

Ramsess · april 30, 2019, 12:08pm

Fikk en lot på 6,10 i dag, håper det var bunnfiske mitt i denne omgang…